Closing Perspectives: Triplets, Oral Therapy, MRD Evolution, and the Future of AML Care

This segment provides final reflections, highlighting how rapidly the AML treatment landscape is advancing and emphasizing the themes that will shape the next decade of care. The conversation revisits the excitement surrounding triplet therapies, which are producing outstanding response rates, particularly combinations involving menin inhibitors, FLT3 inhibitors, IDH inhibitors, and venetoclax-based backbones. Clinicians underscore that optimizing dosing, adjusting schedules, and individualizing therapy are critical to maximizing efficacy while preserving tolerability. They point to the MD Anderson experience as a model for balancing intensity and safety in triplet administration.

The panel also reiterates the growing importance of all-oral regimens, such as oral HMAs combined with targeted inhibitors, which may reduce treatment burden and improve patient quality of life. Early data show strong responses and promising survival, signaling a shift toward more flexible outpatient-based care.

MRD continues to surface as a foundational future tool. The panel highlights emerging MRD assays, particularly new tests for KMT2A-rearranged AML, that exhibit unprecedented sensitivity. As MRD methodology matures, adaptive therapy based on biological response rather than tolerability or protocol-driven schedules is expected to become standard practice.

While recognizing these innovations, the clinicians emphasize the need to remain grounded in evidence. Intensive chemotherapy is not obsolete, especially for mutation-defined favorable-risk AML. Until randomized trials validate less intensive approaches as curative, established regimens remain crucial.

The closing remarks emphasize optimism: AML treatment is changing profoundly, with new tools, deeper remissions, and more personalized strategies reshaping patient outcomes.